{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018158","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.957725+00:00","generated_at":"2026-06-02T13:26:33.392111+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cingulate reports Q1 2024 net loss of $3.0M; CTx-1301 NDA filing on track for 1H 2025","bullets":["Net loss of $3.0M for Q1 2024, down from $4.0M in Q1 2023.","Cash and equivalents $1.1M as of March 31, 2024, up from $52K at Dec 31, 2023.","Raised $10.7M in capital YTD; $3.3M debt converted to equity by Werth Family.","CTx-1301 NDA filing on track for first half of 2025.","Stockholders' equity improved to $3.2M from ($6.9M) at year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018158","json":"https://secwatch.observer/filing/0001493152-24-018158.json","markdown":"https://secwatch.observer/filing/0001493152-24-018158.md","text":"https://secwatch.observer/filing/0001493152-24-018158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315224018158/0001493152-24-018158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315224018158/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T13:26:33.392111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b90bbe7c27d4ac30bfde79461ef0c0faf3e6912c","claim":"Cingulate Inc. reported for the three months ended March 31, 2024 results: net income Net loss was $3.0 million for the three months ended March 31, 2024, EPS Net loss per share of common stock, basic and diluted $ (0.60 ).","evidence_excerpt":"On May 8, 2024, Cingulate Inc. issued a press release announcing its financial results for the first quarter of 2024 and providing a clinical and business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315224018158/0001493152-24-018158-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the three months ended March 31, 2024"},{"label":"Net income","value":"Net loss was $3.0 million for the three months ended March 31, 2024"},{"label":"EPS","value":"Net loss per share of common stock, basic and diluted $ (0.60 )"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}